Castelli S, Thorwarth A, van Schewick C, Wendt A, Astrahantseff K, Szymansky A
J Clin Med. 2024; 13(19).
PMID: 39408056
PMC: 11477708.
DOI: 10.3390/jcm13195995.
El-Serafi I, Steele S
Adv Pharmacol Pharm Sci. 2024; 2024:4862706.
PMID: 38966316
PMC: 11223907.
DOI: 10.1155/2024/4862706.
Quezada-Vidal J, Cruz-Vallejo V, Ortiz-Muniz R, Cervantes-Rios E, Morales-Ramirez P
In Vivo. 2024; 38(4):1719-1730.
PMID: 38936939
PMC: 11215592.
DOI: 10.21873/invivo.13622.
Morimoto H, Ogonuki N, Matoba S, Kanatsu-Shinohara M, Ogura A, Shinohara T
Stem Cell Reports. 2024; 19(4):443-455.
PMID: 38458191
PMC: 11096438.
DOI: 10.1016/j.stemcr.2024.02.003.
Schreib K, Bram D, Zeilhofer U, Muller D, Gungor T, Kramer S
Pharmaceutics. 2024; 16(1).
PMID: 38276491
PMC: 11154452.
DOI: 10.3390/pharmaceutics16010013.
WIN18,446 enhances spermatogonial stem cell homing and fertility after germ cell transplantation by increasing blood-testis barrier permeability.
Morimoto H, Kanatsu-Shinohara M, Shinohara T
J Reprod Dev. 2023; 69(6):347-355.
PMID: 37899250
PMC: 10721852.
DOI: 10.1262/jrd.2023-074.
Hypofibrinolysis in pediatric patients with veno-occlusive disease in hematopoietic stem cell transplantation.
Schneider V, Cabanillas Stanchi K, Althaus K, Schober S, Michaelis S, Seitz C
J Cancer Res Clin Oncol. 2023; 149(11):8443-8453.
PMID: 37086290
PMC: 10374734.
DOI: 10.1007/s00432-023-04798-9.
Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan.
Seydoux C, Satyanarayana Uppugunduri C, Medinger M, Nava T, Halter J, Heim D
Bone Marrow Transplant. 2023; 58(7):811-816.
PMID: 37085674
PMC: 10325946.
DOI: 10.1038/s41409-023-01963-z.
Alginate Oligosaccharides Repair Liver Injury by Improving Anti-Inflammatory Capacity in a Busulfan-Induced Mouse Model.
Hao Y, Fang H, Yan X, Shen W, Liu J, Han P
Int J Mol Sci. 2023; 24(4).
PMID: 36834506
PMC: 9967464.
DOI: 10.3390/ijms24043097.
Population pharmacokinetic model for once-daily intravenous busulfan in pediatric subjects describing time-associated clearance.
Lawson R, Staatz C, Fraser C, Ramachandran S, Teague L, Mitchell R
CPT Pharmacometrics Syst Pharmacol. 2022; 11(8):1002-1017.
PMID: 35611997
PMC: 9381908.
DOI: 10.1002/psp4.12809.
Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation.
Seydoux C, Battegay R, Halter J, Heim D, Rentsch K, Passweg J
Bone Marrow Transplant. 2022; 57(6):903-910.
PMID: 35361896
PMC: 9200635.
DOI: 10.1038/s41409-022-01641-6.
GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation.
Jurkovic Mlakar S, Uppugunduri S, Nava T, Mlakar V, Golay H, Robin S
J Cancer Res Clin Oncol. 2021; 148(1):71-86.
PMID: 34499222
PMC: 8752561.
DOI: 10.1007/s00432-021-03769-2.
Polymorphism Impacts Proinflammatory Cytokine Levels, Survival, and Transplant-Related Mortality After Hematopoietic Stem Cell Transplantation in Adult Patients Receiving Busulfan-Based Conditioning Regimens.
Huang J, Hao C, Li Z, Wang L, Jiang J, Tang W
Front Pharmacol. 2021; 11:563321.
PMID: 33384597
PMC: 7770105.
DOI: 10.3389/fphar.2020.563321.
Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients.
Lawson R, Staatz C, Fraser C, Hennig S
Clin Pharmacokinet. 2020; 60(1):17-51.
PMID: 33128207
DOI: 10.1007/s40262-020-00947-2.
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.
Seydoux C, Medinger M, Gerull S, Halter J, Heim D, Chalandon Y
Ann Hematol. 2020; 100(1):209-216.
PMID: 33098041
PMC: 7782401.
DOI: 10.1007/s00277-020-04312-y.
Prediction of Acute Graft versus Host Disease and Relapse by Endogenous Metabolomic Compounds in Patients Receiving Personalized Busulfan-Based Conditioning.
McCune J, McKiernan J, van Maarseveen E, Huitema A, Randolph T, Deeg H
J Proteome Res. 2020; 20(1):684-694.
PMID: 33064008
PMC: 8214873.
DOI: 10.1021/acs.jproteome.0c00599.
Evaluation of Reversed Administration Order of Busulfan (BU) and Cyclophosphamide (CY) as Conditioning on Liver Toxicity in Allogenic Hematopoietic Stem Cell Transplantation (ALL-HSCT).
Ramzi M, Namdari N, Haghighat S, Haghighinejad H
Int J Hematol Oncol Stem Cell Res. 2020; 14(3):171-176.
PMID: 33024523
PMC: 7521389.
DOI: 10.18502/ijhoscr.v14i3.3725.
Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation.
Bonifazi F, Barbato F, Ravaioli F, Sessa M, Defrancesco I, Arpinati M
Front Immunol. 2020; 11:489.
PMID: 32318059
PMC: 7147118.
DOI: 10.3389/fimmu.2020.00489.
Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation.
El-Serafi I, Remberger M, Ringden O, Torlen J, Sundin M, Bjorklund A
Clin Transl Sci. 2019; 13(2):293-300.
PMID: 31675173
PMC: 7070785.
DOI: 10.1111/cts.12709.
Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.
McCune J, Wang T, Bo-Subait K, Aljurf M, Beitinjaneh A, Bubalo J
Biol Blood Marrow Transplant. 2019; 25(7):1424-1431.
PMID: 30871976
PMC: 6615968.
DOI: 10.1016/j.bbmt.2019.03.001.